The US Food and Drug Administration (FDA) today announced it has approved the
new erythropoiesis-stimulating agent (ESA) peginesatide to treat anemia in
patients receiving dialysis who have chronic kidney disease (CKD).
Peginesatide, which was developed by Affymax in partnership with Takeda
Pharmaceutical Co, will be marketed as Omontys. It works by stimulating the bone
marrow to produce more red blood cells, thus increasing hemoglobin levels and
reducing the need for transfusions in patients with CKD.
This is good news for patients with CKD in England, here I want introduce
another medicine for you which istraditional Chinese CKD medicine. The main goal
of us is to help the patients with CKD, we are sure more new medicines, more
hopes for you. Chinese medicine is helpful with strengthening immunity
syImmunotherapy of human body. So, the body will become more virus-resistant. In
order to avoid Glomerular inflammatory and prevent the aggravation of damaged
renal cells, we need to use traditional Chinese medicine. Instead of restricting
the activity of immunocyte for the purpose of reducing inflammatory response of
renal cells, Chinese medicine aims at strengthening human body’s immunity
ability to protect it from virus invasion. After that, reparative materials
supplied by Chinese medicine will promote the restoration of damaged intrinsic
renal cells and finally restores renal functions. In addition, in order to use
Chinese traditional medicine more effectively, we smashed the medicine into
powder and put them on the skin of patients, then we use electric pulse to place
the medicine to the damaged cells without the pain caused by having orally.
Peginesatide and traditional Chinese CKD medicine are two ways for you to
treat your chronic kidney disease. Wish you cure your chronic kidney disease
earlier.
